8legs: Medicare

Your Followed Topics

#1 out of 3

A STAT opinion urges Congress to ensure Medicare covers breakthrough medical technologies to expand patient access.
The author cites a Stanford study showing an average 5.7-year gap before Medicare provides any coverage for breakthroughs.
The piece describes the valley of death as a barrier to access and innovation in the U.S. medical tech sector.
Legislation cited has previously seen bipartisan support in the House, with a Senate vote pending.
Any Medicare coverage would be limited to technologies within established benefit categories and CMS-reviewed data.

Vote 0

#2 out of 3

Vermonters lost most Medicare Advantage options in 2026 after insurers pulled plans from the state.
Many residents returned to traditional Medicare and faced higher costs without private plans.
Medigap and prescription plan costs rose for some seniors after losing Advantage coverage.
The change expands eligibility for Medicare Savings Program in Vermont, aiding thousands.
Public journalism frames the issue during Sunshine Week, urging support for local reporting.
Vermont residents cited costs rising from Medigap and prescription plans without Advantage coverage.
Customers report varying experiences with the transition, some finding it manageable, others costly.
Stakeholders like SHIP warn about the burden of losing Advantage plans on beneficiaries.
The report highlights individual stories to illustrate the broader policy shift.
The story emphasizes the need for affordable, accessible health coverage amid plan withdrawals.

Vote 0

#3 out of 3

Natera’s oncology testing momentum is building amid growing demand for its assays.
The company cites enrollment and commercial traction driving the uptrend in oncology tests.
Analysts see expanding clinical utility and payer support as factors behind growth.
The discussion frames a favorable long-term outlook for Natera’s oncology portfolio.
The piece notes the clinical and commercial drivers behind the momentum.
Tumor profiling's evolving landscape is highlighted as underpinning growth.
The report implies payer support could broaden access to Natera’s tests.
Commercial traction is cited as a key driver behind the momentum.
The piece suggests a favorable near- and long-term outlook for the stock’s oncology segment.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.